查找临床试验
已按「类风湿关节炎」检索，对应国际通用词 rheumatoid arthritis
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 09:59，每 5 分钟自动同步正在招募早期 I 期中国有中心NCT07246096
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
China
年龄 18 Years – 70 Years
Changhai Hospital
正在招募I 期中国有中心NCT06946641
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
China
年龄 18 Years – 75 Years
Shanghai Qilu Pharmaceutical Research and Development Center LTD
正在招募I 期中国有中心NCT07413341
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Therorna
正在招募不适用中国有中心NCT07052565
CAR-T Cells Therapy for Patients With Autoimmune Diseases
China
年龄 18 Years – 不限
Anhui Provincial Hospital
正在招募I 期 / II 期中国有中心NCT06350110
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
China
年龄 18 Years – 90 Years
Essen Biotech
正在招募不适用中国有中心NCT07045896
Fucoidan in the Treatment of Active Rheumatoid Arthritis
China
年龄 18 Years – 65 Years
Peking University People's Hospital
正在招募不适用中国有中心NCT07301892
Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis
China
年龄 不限 – 不限
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
正在招募早期 I 期中国有中心NCT06888960
Safety Study of CC312 in Autoimmune Disease Patients
China
年龄 18 Years – 不限
CytoCares Inc
正在招募IV 期中国有中心NCT05955066
Effect of JAK Inhibitor on Erosion Healing in RA
Hong Kong
年龄 18 Years – 65 Years
Chinese University of Hong Kong
正在招募不适用中国有中心NCT07126431
Prospective Cohort Study on Refractory Rheumatoid Arthritis
China
年龄 18 Years – 不限
Peking University Third Hospital
正在招募IV 期中国有中心NCT05540938
Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis
China
年龄 18 Years – 75 Years
China-Japan Friendship Hospital
正在招募II 期中国有中心NCT06189495
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
China
年龄 18 Years – 75 Years
Changchun GeneScience Pharmaceutical Co., Ltd.